In a Chinese phase 3 trial (LungTIME-C01) involving 210 patients with advanced non-small cell lung cancer, administering anti-PD-1 immunotherapy before 3:00 PM nearly doubled progression-free survival (11.3 vs. 5.7 months) and significantly improved overall survival (28.0 vs. 16.8 months) compared to later infusions. This early time-of-day treatment was linked to a more robust anti-tumor immune response, characterized by increased levels of activated CD8+ T cells and a more favorable ratio of activated to exhausted T cells, with no increase in treatment-related adverse events. The findings suggest that simply shifting immunochemotherapy to early time-of-day can profoundly enhance efficacy for patients. Source: https://www.nature.com
A secondary MRI analysis of the US POINTER randomized clinical trial found that a structured…
Dementia risk factors vary substantially across countries, but they frequently cluster together in similar patterns…
A systematic review and network meta-analysis of 262 randomized trials involving 99,791 participants found that…
Approximately 21% of patients with phenotypically mild hypertrophic cardiomyopathy (HCM) experienced major adverse cardiovascular events…
A Danish randomized crossover trial found that a single session of high-intensity interval exercise (HIIE)…
Baseline use of proton pump inhibitors (PPIs) and, to a lesser extent, antibiotics was associated…
This website uses cookies.